BFEC
KLRS

Benjamin F. Edwards & Company’s Kalaris Therapeutics KLRS Stock Holding History

Benjamin F. Edwards & Company’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-68
Closed -$31K – 1779
2021
Q2 		$31K Buy
+68
New +$35.1K ﹤0.01% 1134

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Benjamin F. Edwards & Company's KLRS Position: Q3 2021 in Review

Benjamin F. Edwards & Company sold out of Kalaris Therapeutics (KLRS) in Q3 2021, closing a stake of 68 shares — an estimated $31K sold.

Benjamin F. Edwards & Company first reported a position in KLRS in Q2 2021 and held it in 1 quarter. The position peaked at $31K in Q2 2021. 79 funds tracked by Wall St. Rank hold KLRS as of Q3 2021.

  • Benjamin F. Edwards & Company reported no remaining Kalaris Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 68 Kalaris Therapeutics shares in Q3 2021, an estimated $31K.
  • Benjamin F. Edwards & Company first reported a position in Kalaris Therapeutics in Q2 2021 and held it in 1 quarter.
  • Benjamin F. Edwards & Company's Kalaris Therapeutics position peaked at $31K in Q2 2021.
  • 79 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2021.

Based on Benjamin F. Edwards & Company's 13F filing for Q3 2021, filed 2 Nov 2021.